JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

JNJ

192.06

-0.32%↓

ABT

126.47

-1.09%↓

MDT

94.35

-1.76%↓

VEEV

291.35

+0.66%↑

A

147.16

+0.91%↑

Search

Crinetics Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

40.19 -0.64

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

39.79

Макс.

41.05

Ключевые показатели

By Trading Economics

Доход

-19M

-116M

Продажи

670K

1M

Рентабельность продаж

-11,216.004

Сотрудники

437

EBITDA

-19M

-129M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+99.36% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.4B

4B

Предыдущая цена открытия

40.83

Предыдущая цена закрытия

40.19

Новостные настроения

By Acuity

50%

50%

168 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 окт. 2025 г., 22:47 UTC

Приобретения, слияния, поглощения

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 окт. 2025 г., 22:13 UTC

Приобретения, слияния, поглощения

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 окт. 2025 г., 21:20 UTC

Отчет

Correction to IBM 3Q Sales Jump Article

22 окт. 2025 г., 20:57 UTC

Отчет

SAP Posts Higher 3Q Revenue, Operating Profit

22 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

22 окт. 2025 г., 23:46 UTC

Обсуждения рынка

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 окт. 2025 г., 23:41 UTC

Обсуждения рынка

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 окт. 2025 г., 23:38 UTC

Обсуждения рынка

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 окт. 2025 г., 23:15 UTC

Отчет

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 окт. 2025 г., 22:28 UTC

Обсуждения рынка

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 окт. 2025 г., 22:02 UTC

Отчет

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 окт. 2025 г., 21:59 UTC

Приобретения, слияния, поглощения

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 окт. 2025 г., 21:58 UTC

Приобретения, слияния, поглощения

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 окт. 2025 г., 21:57 UTC

Приобретения, слияния, поглощения

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 окт. 2025 г., 21:56 UTC

Приобретения, слияния, поглощения

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 окт. 2025 г., 21:47 UTC

Приобретения, слияния, поглощения

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 окт. 2025 г., 21:47 UTC

Отчет

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 окт. 2025 г., 21:47 UTC

Приобретения, слияния, поглощения

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 окт. 2025 г., 21:46 UTC

Приобретения, слияния, поглощения

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 окт. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 окт. 2025 г., 21:45 UTC

Приобретения, слияния, поглощения

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 окт. 2025 г., 21:28 UTC

Обсуждения рынка
Отчет

Correction to Alcoa Tariff Market Talk

22 окт. 2025 г., 21:25 UTC

Отчет

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 окт. 2025 г., 21:17 UTC

Отчет

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 окт. 2025 г., 21:09 UTC

Обсуждения рынка
Отчет

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 окт. 2025 г., 21:00 UTC

Обсуждения рынка

ESG Roundup: Market Talk

22 окт. 2025 г., 20:59 UTC

Отчет

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 окт. 2025 г., 20:51 UTC

Отчет

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

22 окт. 2025 г., 20:44 UTC

Отчет

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Сравнение c конкурентами

Изменение цены

Crinetics Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

99.36% рост

Прогноз на 12 месяцев

Средняя 80.6 USD  99.36%

Максимум 143 USD

Минимум 40 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Crinetics Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

16 ratings

15

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

30.39 / 33.46Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Neutral Evidence

Настроения

By Acuity

168 / 371Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat